Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

Cancer survivorship and its association with perioperative opioid use for minor non-cancer surgery.

Eiffert S, Nicol AL, Ellerbeck EF, Brooks JV, Roberts AW.

Support Care Cancer. 2020 Mar 25. doi: 10.1007/s00520-020-05420-1. [Epub ahead of print]

PMID:
32215736
2.

Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A.

Blood Rev. 2020 Feb 21:100672. doi: 10.1016/j.blre.2020.100672. [Epub ahead of print] Review.

PMID:
32204955
3.

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells.

Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ, Fedele PL, Low MSY, Grigoriadis G, Harrison SJ, Strasser A, Roberts AW, Huang DCS, Nolan GP, Gray DHD, Ko ME.

Cell Death Differ. 2020 Jan 27. doi: 10.1038/s41418-020-0498-z. [Epub ahead of print]

PMID:
31988495
4.

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, McBean M, Thijssen R, Conway T, Anderson MA, Seymour JF, Westerman DA, Czabotar PE, Huang DCS, Roberts AW.

Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205. No abstract available.

PMID:
31951646
5.

Dynamic post-translational modification profiling of Mycobacterium tuberculosis-infected primary macrophages.

Budzik JM, Swaney DL, Jimenez-Morales D, Johnson JR, Garelis NE, Repasy T, Roberts AW, Popov LM, Parry TJ, Pratt D, Ideker T, Krogan NJ, Cox JS.

Elife. 2020 Jan 17;9. pii: e51461. doi: 10.7554/eLife.51461.

6.

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA, Blombery P, Westerman DA, Wall M, Tam CS, Roberts AW, Seymour JF.

Blood Adv. 2020 Jan 14;4(1):165-173. doi: 10.1182/bloodadvances.2019000864.

7.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH.

Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.

PMID:
31932844
8.

Long-term opioid therapy definitions and predictors: A systematic review.

Karmali RN, Bush C, Raman SR, Campbell CI, Skinner AC, Roberts AW.

Pharmacoepidemiol Drug Saf. 2020 Mar;29(3):252-269. doi: 10.1002/pds.4929. Epub 2019 Dec 18.

PMID:
31851773
9.

New-onset persistent opioid use following breast cancer treatment in older adult women.

Roberts AW, Fergestrom N, Neuner JM, Winn AN.

Cancer. 2020 Feb 15;126(4):814-822. doi: 10.1002/cncr.32593. Epub 2019 Dec 17.

PMID:
31846054
10.

Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.

Speir M, Nowell CJ, Chen AA, O'Donnell JA, Shamie IS, Lakin PR, D'Cruz AA, Braun RO, Babon JJ, Lewis RS, Bliss-Moreau M, Shlomovitz I, Wang S, Cengia LH, Stoica AI, Hakem R, Kelliher MA, O'Reilly LA, Patsiouras H, Lawlor KE, Weller E, Lewis NE, Roberts AW, Gerlic M, Croker BA.

Nat Immunol. 2020 Jan;21(1):54-64. doi: 10.1038/s41590-019-0550-7. Epub 2019 Dec 9.

PMID:
31819256
11.

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.

Dengler MA, Teh CE, Thijssen R, Gangoda L, Lan P, Herold MJ, Gray DH, Kelly GL, Roberts AW, Adams JM.

Oncogene. 2020 Feb;39(9):2009-2023. doi: 10.1038/s41388-019-1122-x. Epub 2019 Nov 26.

PMID:
31772331
12.

The lock-in loophole: Using mixed methods to explain patient circumvention of a Medicaid opioid restriction program.

Roberts AW, Skinner AC, Lauffenburger JC, Galt KA.

Subst Abus. 2019 Oct 23:1-9. doi: 10.1080/08897077.2019.1674239. [Epub ahead of print]

PMID:
31644398
13.

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.

Thijssen R, Roberts AW.

Cancer Cell. 2019 Oct 14;36(4):341-343. doi: 10.1016/j.ccell.2019.09.008.

PMID:
31614111
14.

Concurrent Opioid and Benzodiazepine Prescriptions among Older Women Diagnosed with Breast Cancer.

Check DK, Winn AN, Fergestrom N, Reeder-Hayes KE, Neuner JM, Roberts AW.

J Natl Cancer Inst. 2019 Oct 12. pii: djz201. doi: 10.1093/jnci/djz201. [Epub ahead of print]

PMID:
31605134
15.

Characteristics of New Opioid Use Among Medicare Beneficiaries: Identifying High-Risk Patterns.

Raman SR, Bush C, Karmali RN, Greenblatt LH, Roberts AW, Skinner AC.

J Manag Care Spec Pharm. 2019 Sep;25(9):966-972. doi: 10.18553/jmcp.2019.25.9.966.

16.

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?

Wei AH, Roberts AW.

Cancer Discov. 2019 Aug;9(8):998-1000. doi: 10.1158/2159-8290.CD-19-0575.

PMID:
31371322
17.

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW.

Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24.

18.

Domain swaps of Arabidopsis secondary wall cellulose synthases to elucidate their class specificity.

Hill JL Jr, Hill AN, Roberts AW, Haigler CH, Tien M.

Plant Direct. 2018 Jul 10;2(7):e00061. doi: 10.1002/pld3.61. eCollection 2018 Jul.

19.

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW.

Br J Haematol. 2019 Sep;186(6):e188-e191. doi: 10.1111/bjh.16069. Epub 2019 Jun 24. No abstract available.

PMID:
31234236
20.

Cas9+ conditionally-immortalized macrophages as a tool for bacterial pathogenesis and beyond.

Roberts AW, Popov LM, Mitchell G, Ching KL, Licht DJ, Golovkine G, Barton GM, Cox JS.

Elife. 2019 Jun 17;8. pii: e45957. doi: 10.7554/eLife.45957.

21.

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I.

Haematologica. 2020 Jan 31;105(2):e76-e79. doi: 10.3324/haematol.2019.220590. Print 2020. No abstract available.

22.

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, Blombery P, Lessene G, Majewski IJ, Thijssen R, Roberts AW, Huang DCS, Colman PM, Czabotar PE.

Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.

23.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

24.

Convergent evolution of hetero-oligomeric cellulose synthesis complexes in mosses and seed plants.

Li X, Speicher TL, Dees DCT, Mansoori N, McManus JB, Tien M, Trindade LM, Wallace IS, Roberts AW.

Plant J. 2019 Sep;99(5):862-876. doi: 10.1111/tpj.14366. Epub 2019 May 25.

PMID:
31021018
25.

Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.

Naumann RB, Roberts AW, Marshall SW, Skinner AC.

Med Care. 2019 Mar;57(3):213-217. doi: 10.1097/MLR.0000000000001058.

26.

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A.

Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004. Review.

27.

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.

Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ.

Cancer Discov. 2019 Mar;9(3):354-369. doi: 10.1158/2159-8290.CD-18-1151. Epub 2018 Dec 5.

28.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

29.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
30.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
31.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25. Erratum in: Cancer Discov. 2019 Jul;9(7):980.

32.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.

Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10.

33.

A Map of Toll-like Receptor Expression in the Intestinal Epithelium Reveals Distinct Spatial, Cell Type-Specific, and Temporal Patterns.

Price AE, Shamardani K, Lugo KA, Deguine J, Roberts AW, Lee BL, Barton GM.

Immunity. 2018 Sep 18;49(3):560-575.e6. doi: 10.1016/j.immuni.2018.07.016. Epub 2018 Aug 28.

34.

Glycaemic management during the inpatient enteral feeding of people with stroke and diabetes.

Roberts AW, Penfold S; Joint British Diabetes Societies (JBDS) for Inpatient Care.

Diabet Med. 2018 Aug;35(8):1027-1036. doi: 10.1111/dme.13678.

PMID:
30152589
35.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ.

Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.

36.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

37.

Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.

Roberts AW, Saloner B, Dusetzina SB.

Psychiatr Serv. 2018 Jul 1;69(7):832-835. doi: 10.1176/appi.ps.201700315. Epub 2018 May 8.

38.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. Erratum in: J Clin Oncol. 2019 Sep 1;37(25):2299.

PMID:
29715056
39.

Functional Characterization of a Glycosyltransferase from the Moss Physcomitrella patens Involved in the Biosynthesis of a Novel Cell Wall Arabinoglucan.

Roberts AW, Lahnstein J, Hsieh YSY, Xing X, Yap K, Chaves AM, Scavuzzo-Duggan TR, Dimitroff G, Lonsdale A, Roberts E, Bulone V, Fincher GB, Doblin MS, Bacic A, Burton RA.

Plant Cell. 2018 Jun;30(6):1293-1308. doi: 10.1105/tpc.18.00082. Epub 2018 Apr 19.

40.

Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.

Roberts AW, Carpenter DM, Smith A, Look KA.

Res Social Adm Pharm. 2019 Feb;15(2):222-225. doi: 10.1016/j.sapharm.2018.04.002. Epub 2018 Apr 5.

41.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

42.

Cellulose synthase 'class specific regions' are intrinsically disordered and functionally undifferentiated.

Scavuzzo-Duggan TR, Chaves AM, Singh A, Sethaphong L, Slabaugh E, Yingling YG, Haigler CH, Roberts AW.

J Integr Plant Biol. 2018 Jun;60(6):481-497. doi: 10.1111/jipb.12637. Epub 2018 Mar 30.

PMID:
29380536
43.

Direct observation of the effects of cellulose synthesis inhibitors using live cell imaging of Cellulose Synthase (CESA) in Physcomitrella patens.

Tran ML, McCarthy TW, Sun H, Wu SZ, Norris JH, Bezanilla M, Vidali L, Anderson CT, Roberts AW.

Sci Rep. 2018 Jan 15;8(1):735. doi: 10.1038/s41598-017-18994-4.

44.

Venetoclax: a primer.

Roberts AW.

Blood Adv. 2017 Feb 28;1(7):467. doi: 10.1182/bloodadvances.2017000547. eCollection 2017 Feb 28. No abstract available.

45.

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A.

Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16. No abstract available.

PMID:
29263442
46.

Tissue-Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells.

Roberts AW, Lee BL, Deguine J, John S, Shlomchik MJ, Barton GM.

Immunity. 2017 Nov 21;47(5):913-927.e6. doi: 10.1016/j.immuni.2017.10.006. Epub 2017 Nov 14.

47.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

PMID:
28847998
48.

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.

Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A.

Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502.

PMID:
28782211
49.

Functional Specialization of Cellulose Synthase Isoforms in a Moss Shows Parallels with Seed Plants.

Norris JH, Li X, Huang S, Van de Meene AML, Tran ML, Killeavy E, Chaves AM, Mallon B, Mercure D, Tan HT, Burton RA, Doblin MS, Kim SH, Roberts AW.

Plant Physiol. 2017 Sep;175(1):210-222. doi: 10.1104/pp.17.00885. Epub 2017 Aug 2.

50.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770

Supplemental Content

Loading ...
Support Center